Alzheimer’s disease remains one of the most challenging neurodegenerative disorders, affecting more than 7 million people in the United States alone, with current therapies offering only modest slowing of cognitive decline. A recent Phase 2/3 clinical study evaluating buntanetap, an orally available small molecule designed to inhibit the translation of multiple neurotoxic proteins including amyloid precursor protein (APP), Tau, α-synuclein, and TDP43, explores whether a multi-target approach could provide broader therapeutic benefit.
The study was a 3-month, randomized, double-blind, dose-ranging trial (NCT05686044) involving 351 patients with mild to moderate Alzheimer’s disease, selected from 701 screened participants across 54 sites in the United States. Patients were randomized in a 1:1:1:1 ratio to receive 7.5 mg, 15 mg, or 30 mg of buntanetap or placebo over 12 weeks. The study population included individuals aged 55 to 85 years, with a mean age of 73.6 years, and between 50.6% and 65.5% female participants, while over 41% represented racial and ethnic minority groups. The primary endpoints were change from baseline in ADAS-Cog11 scores and the Alzheimer’s Disease Cooperative Study–Clinical Global Impression of Change (ADCS-CGIC) at week 12.
The trial did not meet its primary endpoints, as both buntanetap and placebo groups showed similar improvements in cognitive and functional measures, with an ADAS-Cog11 difference of 0.13 (95% CI: −1.088 to 1.350; p = 0.833) and an ADCS-CGIC difference of 0.22 (95% CI: −0.074 to 0.516; p = 0.141). A key contributing factor was that approximately 40% of enrolled participants lacked amyloid pathology, meaning they did not meet the biological definition of Alzheimer’s disease. However, in post-hoc analyses focusing on biomarker-positive patients, who comprised 62.1% (n = 216) of the study population, buntanetap demonstrated dose-dependent cognitive improvement in patients with mild Alzheimer’s disease (MMSE 21–24), with treatment effects becoming more apparent by week 12 as placebo responses diminished.
Safety outcomes were favorable, with the drug being well tolerated across all dose groups. Treatment-emergent adverse events occurred in 33.3% of buntanetap-treated patients compared with 26.1% in the placebo group, while drug-related adverse events were reported in 8.9% versus 3.4%, respectively. Serious adverse events were observed in 3.4% of patients in both the 30 mg and placebo groups, with none considered related to the study drug, and all adverse events were mild to moderate with no severe cases reported.
Biomarker analyses further supported buntanetap’s mechanism of action, showing that the 30 mg dose reduced multiple markers associated with neurodegeneration and inflammation, including t-Tau, TDP43, IL-5, IL-6, S100A12, IFN-γ, IGF1R, and neurofilament light (NFL), suggesting potential disease-modifying activity. These findings highlight the importance of targeting multiple pathological pathways in Alzheimer’s disease, particularly in biomarker-confirmed patient populations, and reinforce the need for precision in patient selection for clinical trials.
Building on these results, a larger Phase 3 study (NCT06709014) involving 760 patients over 18 months is currently underway in biomarker-confirmed early Alzheimer’s disease, aiming to validate both the symptomatic and potential disease-modifying effects of buntanetap.
Source Credit:
Fang, C., Feng, D., Gaines, M., Laskowitz, D., Sanders, L. H., Liow, K., et al. (2026). Buntanetap treatment in mild to moderate Alzheimer’s disease: Phase 2/3 study. npj Dementia. Click here
